JP4346269B2 - Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体 - Google Patents

Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体 Download PDF

Info

Publication number
JP4346269B2
JP4346269B2 JP2001507845A JP2001507845A JP4346269B2 JP 4346269 B2 JP4346269 B2 JP 4346269B2 JP 2001507845 A JP2001507845 A JP 2001507845A JP 2001507845 A JP2001507845 A JP 2001507845A JP 4346269 B2 JP4346269 B2 JP 4346269B2
Authority
JP
Japan
Prior art keywords
group
pyrimidin
thieno
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001507845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503504A5 (https=
JP2003503504A (ja
Inventor
ロジャー ジョン ジルズパイ，
ポール リチャード ジルズ，
ジョアン ラーピニーア，
クレア エリザベス ドーソン，
デイビッド ベッビントン，
Original Assignee
バーナリス リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーナリス リサーチ リミテッド filed Critical バーナリス リサーチ リミテッド
Publication of JP2003503504A publication Critical patent/JP2003503504A/ja
Publication of JP2003503504A5 publication Critical patent/JP2003503504A5/ja
Application granted granted Critical
Publication of JP4346269B2 publication Critical patent/JP4346269B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001507845A 1999-07-01 2000-06-30 Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体 Expired - Fee Related JP4346269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9915437.9 1999-07-01
GBGB9915437.9A GB9915437D0 (en) 1999-07-01 1999-07-01 Chemical compounds III
PCT/GB2000/002517 WO2001002409A1 (en) 1999-07-01 2000-06-30 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists

Publications (3)

Publication Number Publication Date
JP2003503504A JP2003503504A (ja) 2003-01-28
JP2003503504A5 JP2003503504A5 (https=) 2007-08-09
JP4346269B2 true JP4346269B2 (ja) 2009-10-21

Family

ID=10856458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001507845A Expired - Fee Related JP4346269B2 (ja) 1999-07-01 2000-06-30 Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体

Country Status (9)

Country Link
US (1) US6787541B1 (https=)
EP (1) EP1192164B1 (https=)
JP (1) JP4346269B2 (https=)
AT (1) ATE302205T1 (https=)
AU (1) AU5557800A (https=)
CA (1) CA2370344C (https=)
DE (1) DE60022042T2 (https=)
GB (1) GB9915437D0 (https=)
WO (1) WO2001002409A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US20050239782A1 (en) * 2001-04-18 2005-10-27 Heintzelman Geoffrey R Arylindenopyridines and related therapeutic and prophylactic methods
US6903109B2 (en) * 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
CN101543497A (zh) * 2002-01-28 2009-09-30 协和发酵工业株式会社 治疗运动疾病患者的方法
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
US7429584B2 (en) 2002-07-11 2008-09-30 Bayer Pharmaceuticals Corporation Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
JP2006514697A (ja) * 2002-12-19 2006-05-11 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニストの使用
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
EP1615930A2 (en) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US20070010522A1 (en) * 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
US7923448B2 (en) * 2003-11-03 2011-04-12 Cornell Research Foundation, Inc. Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
JP5089395B2 (ja) 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
CN102504001B (zh) * 2004-12-17 2015-02-25 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
JP2008537961A (ja) * 2005-04-15 2008-10-02 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ Ｇｐｃｒモジュレーター
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
GB0718434D0 (en) 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718432D0 (en) 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093723A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093722A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
WO2011133696A2 (en) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Methods of suppressing atherosclerosis
CN102408433B (zh) * 2011-10-20 2014-04-09 天津药物研究院 含嘧啶的肟类化合物、其制备方法和用途
CN102503953B (zh) * 2011-10-20 2014-02-19 天津药物研究院 肟类化合物
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
CN111629728A (zh) * 2017-08-31 2020-09-04 科尔沃斯制药股份有限公司 用于调节腺苷a2b受体和腺苷a2a受体的化合物和方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800776A (es) 1995-07-28 1998-04-30 Abbott Lab Furopiridina, tienopiridina, pirrolopiridina y compuestos de triazina, piridazina y pirimidina relacionados utiles para controlar la transmision sinaptica quimica.
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Also Published As

Publication number Publication date
EP1192164B1 (en) 2005-08-17
DE60022042T2 (de) 2006-06-29
ATE302205T1 (de) 2005-09-15
US6787541B1 (en) 2004-09-07
AU5557800A (en) 2001-01-22
GB9915437D0 (en) 1999-09-01
WO2001002409A1 (en) 2001-01-11
CA2370344A1 (en) 2001-01-11
CA2370344C (en) 2010-09-07
DE60022042D1 (de) 2005-09-22
EP1192164A1 (en) 2002-04-03
JP2003503504A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
JP4346269B2 (ja) Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体
JP4284069B2 (ja) プリン作動性レセプターアンタゴニストとしてのプリン誘導体
JP4287146B2 (ja) トリアゾロ［４，５−ｄ］ピリミジン誘導体およびプリン作用性レセプターアンタゴニストとしてのこれらの使用
US7087754B2 (en) Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用
JP4390454B2 (ja) チエノ（３，２−ｄ）ピリミジンおよびフラノ（３，２−ｄ）ピリミジン、ならびにそれらのプリン作動性レセプターアンタゴニストとしての使用
EP1107761A2 (en) 4-quinolinemethanol derivatives as purine receptor antagonists (ii)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090616

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090714

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120724

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees